| [1] |
Simms RJ. Autosomal dominant polycystic kidney disease [J]. BMJ, 2016, 352: i679.
|
| [2] |
The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16 [J]. Cell, 1994, 78(4): 725.
|
| [3] |
Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein [J]. Science, 1996, 272(5266): 1339-1342.
|
| [4] |
Jin M, Xie Y, Chen Z, et al. System analysis of gene mutations and clinical phenotype in Chinese patients with autosomal-dominant polycystic kidney disease [J]. Sci Rep, 2016, 6: 35945.
|
| [5] |
Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells [J]. Nat Genet, 2003, 33(2): 129-137.
|
| [6] |
Aguilar A. Polycystic kidney disease: PC2 function: insights from the cold [J]. Nat Rev Nephrol, 2017, 13(3): 136.
|
| [7] |
Bankir L, Bichet DG. Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD [J]. Nat Rev Nephrol, 2012，8(8): 437-439.
|
| [8] |
Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease [J]. J Am Soc Nephrol, 2014, 25(1): 18-32.
|
| [9] |
Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease [J]. J Clin Invest, 2014, 124(6): 2315-2324.
|
| [10] |
Wu G, D′Agati V, Cai Y, et al. Somatic inactivation of Pkd2 results in polycystic kidney disease [J]. Cell, 1998, 93(2): 177-188.
|
| [11] |
Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity [J]. J Clin Invest, 2012, 122(11): 4257-4273.
|
| [12] |
Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1 [J]. Nat Med, 2007, 13(12): 1490-1495.
|
| [13] |
Rowe I, Chiaravalli M, Mannella V, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy [J]. Nat Med, 2013, 19(4): 488-493.
|
| [14] |
Werder AA, Amos MA, Nielsen AH, et al. Comparative effects of germfree and ambient environments on the development of cystic kidney disease in CFWwd mice [J]. J Lab Clin Med, 1984, 103(3): 399-407.
|
| [15] |
Gardner KD Jr, Burnside JS, Elzinga LW, et al. Cytokines in fluids from polycystic kidneys [J]. Kidney Int, 1991, 39(4): 718-724.
|
| [16] |
Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD [J]. J Am Soc Nephrol, 2008, 19(9): 1659-1662.
|
| [17] |
Chen D, Ma Y, Wang X, et al. Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial [J]. Am J Kidney Dis, 2014, 63(6): 1070-1072.
|
| [18] |
Grantham JJ, Chapman AB, Blais J, et al. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease [J]. Nephrol Dial Transplant, 2016, [Epub ahead of print]．
|
| [19] |
Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist [J]. Nat Med, 2003, 9(10): 1323-1326.
|
| [20] |
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease [J]. N Engl J Med, 2012, 367(25): 2407-2418.
|
| [21] |
Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease [J]. Ann Intern Med, 2013, 159(6): 382-389.
|
| [22] |
Torres VE, Devuyst O, Chapman AB, et al. Rationale and design of a clinical trial investigating tolvaptan safety and efficacy in autosomal dominant polycystic kidney disease [J]. Am J Nephrol, 2017, 45(3): 257-266.
|
| [23] |
Masyuk TV, Radtke BN, Stroope AJ, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases [J]. Hepatology, 2013, 58(1): 409-421.
|
| [24] |
Caroli A, Perico N, Perna A, et al. Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial [J]. Lancet, 2013, 382(9903): 1485-1495.
|
| [25] |
Hopp K, Hommerding CJ, Wang X, et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model [J]. J Am Soc Nephrol, 2015, 26(1): 39-47.
|
| [26] |
Sweeney WE Jr, von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease [J]. J Am Soc Nephrol, 2008, 19(7): 1331-1341.
|
| [27] |
Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation [J]. Am J Physiol Cell Physiol, 2011, 301(2): C522-C529.
|
| [28] |
Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells [J]. Am J Physiol Renal Physiol, 2010, 299(5): F944-F951.
|
| [29] |
Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease [J]. J Am Soc Nephrol, 2005, 16(1): 46-51.
|
| [30] |
Xue C, Dai B, Mei C. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis [J]. Nephron Clin Pract, 2013, 124(1-2): 10-16.
|
| [31] |
Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease [J]. J Am Soc Nephrol, 2012, 23(5): 842-853.
|
| [32] |
Shillingford JM, Leamon CP, Vlahov IR, et al. Folate-conjugated rapamycin slows progression of polycystic kidney disease [J]. J Am Soc Nephrol, 2012, 23(10): 1674-1681.
|
| [33] |
Ravichandran K, Zafar I, He Z, et al. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2 [J]. Hum Mol Genet, 2014, 23(18): 4919-4931.
|
| [34] |
Zhu P, Sieben CJ, Xu X, et al. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model [J]. Hum Mol Genet, 2016, [Epub ahead of print]．
|
| [35] |
Rowe I, Boletta A. Defective metabolism in polycystic kidney disease: potential for therapy and open questions [J]. Nephrol Dial Transplant, 2014, 29(8): 1480-1486.
|
| [36] |
Riwanto M, Kapoor S, Rodriguez D, et al. Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease [J]. PLoS One, 2016, 11(1): e0146654.
|
| [37] |
Hallows KR, Raghuram V, Kemp BE, et al. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase [J]. J Clin Invest, 2000, 105(12): 1711-1721.
|
| [38] |
Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival [J]. Cell, 2003, 115(5): 577-590.
|
| [39] |
Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis [J]. Proc Natl Acad Sci USA, 2011, 108(6): 2462-2467.
|
| [40] |
Warner G, Hein KZ, Nin V, et al. Food restriction ameliorates the development of polycystic kidney disease [J]. J Am Soc Nephrol, 2016, 27(5): 1437-1447.
|
| [41] |
Kipp KR, Rezaei M, Lin L, et al. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease [J]. Am J Physiol Renal Physiol, 2016, [Epub ahead of print]．
|
| [42] |
Weimbs T, Olsan EE, Talbot JJ. Regulation of STATs by polycystin-1 and their role in polycystic kidney disease [J]. JAKSTAT, 2013, 2(2): e23650.
|
| [43] |
Takakura A, Nelson EA, Haque N, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways [J]. Hum Mol Genet, 2011, 20(21): 4143-4154.
|
| [44] |
Fragiadaki M, Lannoy M, Themanns M, et al. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease [J]. Kidney Int, 2017, 91(3): 575-586.
|
| [45] |
Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease [J]. Nat Med, 2008, 14(8): 863-868.
|
| [46] |
Zhou JX, Fan LX, Li X, et al. TNFalpha signaling regulates cystic epithelial cell proliferation through Akt/mTOR and ERK/MAPK/Cdk2 mediated Id2 signaling [J]. PLoS One, 2015, 10(6): e0131043.
|
| [47] |
Wu M, Gu J, Mei S, et al. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor kappaB-induced inflammation [J]. Nephrol Dial Transplant, 2016, 31(11): 1826-1834.
|
| [48] |
Chen L, Zhou X, Fan LX, et al. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease [J]. J Clin Invest, 2015, 125(6): 2399-2412.
|
| [49] |
Karihaloo A, Koraishy F, Huen SC, et al. Macrophages promote cyst growth in polycystic kidney disease [J]. J Am Soc Nephrol, 2011, 22(10): 1809-1814.
|
| [50] |
Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease [J]. N Engl J Med, 2014, 371(24): 2267-2276.
|
| [51] |
Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease [J]. N Engl J Med, 2014, 371(24): 2255-2266.
|
| [52] |
Saigusa T, Dang Y, Mullick AE, et al. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model [J]. FASEB J, 2016, 30(1): 370-379.
|
| [53] |
Xia S, Li X, Johnson T, et al. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts [J]. Development, 2010, 137(7): 1075-1084.
|
| [54] |
Li X. Epigenetics and autosomal dominant polycystic kidney disease [J]. Biochim Biophys Acta, 2011, 1812(10): 1213-1218.
|
| [55] |
Zhou X, Fan LX, Sweeney WE Jr, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease [J]. J Clin Invest, 2013, 123(7): 3084-3098.
|
| [56] |
van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease [J]. Nephrol Dial Transplant, 2001, 16(11): 2152-2157.
|
| [57] |
Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease [J]. Clin J Am Soc Nephrol, 2014, 9(5): 889-896.
|
| [58] |
Klawitter J, McFann K, Pennington AT, et al. Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease [J]. Clin J Am Soc Nephrol, 2015, 10(9): 1534-1541.
|